Population-specific considerations
| Population | What is supported | What remains unknown | Practical implication |
|---|---|---|---|
| Pregnancy | Neonatal withdrawal reported after prenatal kratom exposure in published cases. | Direct concentrated-7-OH fetal PK, teratogenicity, and preferred induction strategy. | Avoid abrupt unsupported cessation. Coordinate addiction medicine and obstetrics; use established pregnancy OUD principles. |
| Lactation | No dependable direct safety dataset; opioid-active alkaloids could plausibly enter milk. | Milk concentrations and infant outcomes for 7-OH/MP/MGM. | Specialist assessment; monitor infants for sedation, poor feeding, respiratory difficulty, or withdrawal if exposure changes. |
| Children / adolescents | Poison-center reports and candy-like formulations create accidental-ingestion risk. | Pediatric dose-response and neurodevelopmental effects. | Significant ingestion → Poison Help / medical assessment. Store locked; “child-resistant” is not child-proof. |
| Older / frail adults | Greater vulnerability to sedation, falls, delirium, respiratory depression, and polypharmacy. | No geriatric 7-OH trials or validated adjustments. | Lower threshold for monitored care, medication reconciliation, ECG/electrolytes, cognition and falls assessment. |
| Seizure disorder | Seizures appear in surveillance/cases; attribution often confounded. | Incidence, threshold dose, antiseizure interactions. | Raises threshold for home withdrawal; avoid dehydration, sleep deprivation, and abrupt sedative withdrawal. |
| Cardiac / arrhythmia risk | Tachycardia/hypertension in reports; mitragynine inhibits hERG in vitro; SVT described in a 7-OH case. | Isolated-7-OH QT risk and arrhythmia incidence. | ECG/electrolytes when toxicity, syncope, chest symptoms, channelopathy, or QT-prolonging polypharmacy. |
| Respiratory disease / sleep apnea | Opioid respiratory depression in animal models; severe human opioid-like toxicity reported. | Risk by dose, OSA severity, COPD, obesity hypoventilation, PAP use. | Avoid sedative combinations; naloxone; consider monitored initiation when reserve is limited. |
| Hepatic / renal disease | Kratom-associated liver injury in broader product literature; metabolites recovered in urine; secondary kidney injury from dehydration/rhabdo possible. | Isolated 7-OH hepatotoxicity and dosing in CKD/hepatic failure. | Review LFTs/products when symptomatic; correct volume/electrolytes; conservative monitored care in advanced disease. |
| Psychiatric illness / chronic pain | Anxiety, dysphoria, insomnia, craving, and agitation occur in intoxication/withdrawal; many users start for pain. | Distinct 7-OH psychiatric syndromes; comparative analgesic outcomes. | Assess suicide risk and coingestants; build a parallel pain plan before removing the opioid alone. |
Highest-concern combinations
- Alcohol, benzodiazepines, other opioids/fentanyl, gabapentinoids, sedating sleep agents, sedating antihistamines, antipsychotics, muscle relaxants — additive sedation and respiratory depression. Exact 7-OH interaction magnitude is unknown; “partial agonist” is not reassurance.
- Unprescribed opioids to self-treat withdrawal — overdose and counterfeit fentanyl risk; no reliable 7-OH-to-other-opioid conversion.
- Naltrexone while still dependent — precipitated withdrawal risk; confirm adequate opioid-free status clinically.
Metabolic interactions (boundary language)
Mitragynine converts to 7-OH largely via CYP3A pathways (with contributions from CYP2C19/CYP2D6 in some work). Controlled human data show CYP3A inhibition can change the parent–metabolite balance after botanical/mitragynine exposure, and low-dose kratom tea can inhibit intestinal CYP3A. Those findings do not license a universal interaction table for high-dose purified 7-OH products.
Potential CYP3A inhibitors (azoles, some macrolides, protease inhibitors, grapefruit) and inducers (rifampin, carbamazepine, phenytoin, St. John’s wort) may matter differently depending on whether the patient is ingesting mitragynine that must convert versus ingesting 7-OH directly. Commercial mixtures make prediction worse.
Buprenorphine or methadone with benzodiazepines
Concurrent benzodiazepines increase sedation and overdose risk, but they are not an automatic reason to deny evidence-based OUD medication. FDA advises that buprenorphine and methadone should not be withheld solely because of benzodiazepine or other CNS-depressant use; careful management is required. Assess whether benzodiazepine dependence itself needs a coordinated plan.
Monitoring
A negative routine opioid immunoassay does not exclude 7-OH. Use targeted LC-MS/MS or HRMS when confirmation would change care. Drive ECG, electrolytes, renal/hepatic tests, CK, pregnancy testing, and coingestant panels from presentation—not as a ceremonial toxicology set.
Clinicians · Treatment · Pharmacology · Full resource · Downloads